TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation and proposals related to the COVID-19 crisis. Drug pricing proposals in Congress and from the Executive Branch. Proposals designed to increase utilization of biosimilar medicines. Proposals to abrogate 180-day exclusivity for certain generic medicines. Proposals to change pharmaceutical patent laws. Proposals to restrict settlements of pharmaceutical patent disputes. Proposals to improve pharmaceutical supply-chain vulnerabilities. Proposals to retain and attract greater domestic manufacturing of pharmaceuticals. Proposals to change Medicare and Medicaid benefit design. Proposals to improve the drug approval process for generic medicines. S.164, Advancing Education on Biosimilars Act of 2021. S. 415, a bill to amend the Federal Food, Drug & Cosmetic Act with respect to the scope of new chemical exclusivity. Implementation of the Food & Drug Reauthorization Act (PL 115-52). Nomination of the HHS Secretary. Proposals to abrogate pharmaceutical patents used in the COVID-19 pandemic.
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BRZICA | — |
| DOLLY A JUDGE | — |
| BEENA S PATEL New | — |
| COLMAN BRENDAN RAGAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.